152 related articles for article (PubMed ID: 15453039)
21. Anti-TNF-alpha (infliximab) used as induction treatment in case of active proctitis in a multistep strategy followed by definitive surgery of complex anal fistulas in Crohn's disease: a preliminary report.
van der Hagen SJ; Baeten CG; Soeters PB; Russel MG; Beets-Tan RG; van Gemert WG
Dis Colon Rectum; 2005 Apr; 48(4):758-67. PubMed ID: 15750797
[TBL] [Abstract][Full Text] [Related]
22. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
Hyams J; Crandall W; Kugathasan S; Griffiths A; Olson A; Johanns J; Liu G; Travers S; Heuschkel R; Markowitz J; Cohen S; Winter H; Veereman-Wauters G; Ferry G; Baldassano R;
Gastroenterology; 2007 Mar; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
[TBL] [Abstract][Full Text] [Related]
23. Toxicity of infliximab in the course of treatment of Crohn's disease.
Bratcher JM; Korelitz BI
Expert Opin Drug Saf; 2006 Jan; 5(1):9-16. PubMed ID: 16370952
[TBL] [Abstract][Full Text] [Related]
24. [Development of tuberculosis after treatment with the TNF-alpha inhibitor infliximab].
Dahl M; Ravn P
Ugeskr Laeger; 2005 Jan; 167(5):527-8. PubMed ID: 15745179
[No Abstract] [Full Text] [Related]
25. The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease.
Moss AC; Fernandez-Becker N; Jo Kim K; Cury D; Cheifetz AS
Aliment Pharmacol Ther; 2008 Jul; 28(2):221-7. PubMed ID: 18485127
[TBL] [Abstract][Full Text] [Related]
26. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?
Domènech E; Hinojosa J; Nos P; Garcia-Planella E; Cabré E; Bernal I; Gassull MA
Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1107-13. PubMed ID: 16305724
[TBL] [Abstract][Full Text] [Related]
27. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease.
Lichtenstein GR; Olson A; Travers S; Diamond RH; Chen DM; Pritchard ML; Feagan BG; Cohen RD; Salzberg BA; Hanauer SB; Sandborn WJ
Am J Gastroenterol; 2006 May; 101(5):1030-8. PubMed ID: 16606351
[TBL] [Abstract][Full Text] [Related]
28. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
Asteria CR; Ficari F; Bagnoli S; Milla M; Tonelli F
Scand J Gastroenterol; 2006 Sep; 41(9):1064-72. PubMed ID: 16938720
[TBL] [Abstract][Full Text] [Related]
29. Prolonged paradoxical response to anti-tuberculous treatment after infliximab.
Melboucy-Belkhir S; Flexor G; Stirnemann J; Morin AS; Boukari L; Polliand C; Cruaud P; Fain O
Int J Infect Dis; 2010 Sep; 14 Suppl 3():e333-4. PubMed ID: 20579914
[TBL] [Abstract][Full Text] [Related]
30. Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn's disease: a prospective study.
Ryan BM; Russel MG; Schurgers L; Wichers M; Sijbrandij J; Stockbrugger RW; Schoon E
Aliment Pharmacol Ther; 2004 Oct; 20(8):851-7. PubMed ID: 15479356
[TBL] [Abstract][Full Text] [Related]
31. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
Rutgeerts P; Van Assche G; Vermeire S
Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
[TBL] [Abstract][Full Text] [Related]
32. Difficult diagnosis of infliximab-related miliary tuberculosis.
Contini S; Raimondi G; Graziano P; Saltini C; Bocchino M
Monaldi Arch Chest Dis; 2004; 61(2):128-30. PubMed ID: 15510715
[TBL] [Abstract][Full Text] [Related]
33. Onset of flexural psoriasis during infliximab treatment for Crohn's disease.
Peramiquel L; Puig L; Dalmau J; Ricart E; Roe E; Alomar A
Clin Exp Dermatol; 2005 Nov; 30(6):713-4. PubMed ID: 16197398
[No Abstract] [Full Text] [Related]
34. Clinical challenges and images in GI. Oral lichenoid reaction in a patient with Crohn's disease receiving infliximab.
Moss AC; Treister NS; Marsee DK; Cheifetz AS
Gastroenterology; 2007 Feb; 132(2):488, 829. PubMed ID: 17261307
[No Abstract] [Full Text] [Related]
35. Fatal aseptic meningoencephalitis following infliximab treatment for inflammatory bowel disease.
Quispel R; van der Worp HB; Pruissen M; Schipper ME; Oldenburg B
Gut; 2006 Jul; 55(7):1056. PubMed ID: 16766769
[No Abstract] [Full Text] [Related]
36. Disseminated aspergillosis following infliximab therapy in an immunosuppressed patient with Crohn's disease and chronic hepatitis C: a case study and review of the literature.
Alderson JW; Van Dinter TG; Opatowsky MJ; Burton EC
MedGenMed; 2005 Sep; 7(3):7. PubMed ID: 16369233
[TBL] [Abstract][Full Text] [Related]
37. Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions.
Duburque C; Lelong J; Iacob R; Seddik M; Desreumaux P; Fournier C; Wallaert B; Cortot A; Colombel JF
Aliment Pharmacol Ther; 2006 Sep; 24(5):851-8. PubMed ID: 16918890
[TBL] [Abstract][Full Text] [Related]
38. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
Hlavaty T; Pierik M; Henckaerts L; Ferrante M; Joossens S; van Schuerbeek N; Noman M; Rutgeerts P; Vermeire S
Aliment Pharmacol Ther; 2005 Oct; 22(7):613-26. PubMed ID: 16181301
[TBL] [Abstract][Full Text] [Related]
39. Psoriasiform and pustular eruption induced by infliximab.
Takahashi H; Hashimoto Y; Ishida-Yamamoto A; Ashida T; Kohgo Y; Iizuka H
J Dermatol; 2007 Jul; 34(7):468-72. PubMed ID: 17584325
[TBL] [Abstract][Full Text] [Related]
40. Transient type III atrioventricular block after infliximab infusion in a fistulizing perianal Crohn's disease patient.
Sofos S; Savoye G; Ramirez S; Bauer F; Lerebours E
Am J Gastroenterol; 2007 Jan; 102(1):217-9. PubMed ID: 17278277
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
